Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacotherapy and Intensive Treatment - 2

This study has been completed.
VA Office of Research and Development
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: March 23, 2009
Last verified: March 2009
The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.

Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
Drug: Carbamazepine
Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacotherapy and Intensive Treatment

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Severity addiction
  • Depression
  • Depression, anxiety

Estimated Enrollment: 353
Study Completion Date: June 2005

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000218

United States, Missouri
University of Kansas
Kansas City, Missouri, United States, 64128
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
VA Office of Research and Development
Principal Investigator: William Haning, M.D. University of Kansas
  More Information Identifier: NCT00000218     History of Changes
Other Study ID Numbers: NIDA-06954-2  R18-06954-2 
Study First Received: September 20, 1999
Last Updated: March 23, 2009
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Substance-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action processed this record on October 21, 2016